BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 10727003)

  • 1. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
    Perros P
    J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
    Schlumberger MJ; Incerti C; Pacini F; Reiners C
    J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human thyroid-stimulating hormone (rhTSH): clinical development.
    Incerti C
    J Endocrinol Invest; 1999; 22(11 Suppl):8-16. PubMed ID: 10727000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
    Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
    Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131.
    Reiners C; Luster M; Lassmann M
    J Endocrinol Invest; 1999; 22(11 Suppl):17-24. PubMed ID: 10727001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.
    Pacini F; Lippi F
    J Endocrinol Invest; 1999; 22(11 Suppl):25-9. PubMed ID: 10727002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
    Pacini F; Castagna MG
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.
    Zanotti-Fregonara P; Toubert ME; Taieb D; Ravasi L; Rubello D; Hindie E
    Minerva Endocrinol; 2008 Jun; 33(2):53-65. PubMed ID: 18332849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
    Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
    J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy.
    Molinaro E; Viola D; Passannanti P; Agate L; Lippi F; Ceccarelli C; Pinchera A; Elisei R
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):490-502. PubMed ID: 19910902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
    Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
    Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
    Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
    Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.